<DOC>
	<DOCNO>NCT00041327</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Antiviral therapy may kill virus HTLV-1 cause cancer . Interferon alfa may interfere growth cancer cell . Combining chemotherapy antiviral drug interferon alfa may effective treat adult T-cell leukemia/lymphoma . PURPOSE : Phase II trial determine effectiveness combination chemotherapy follow antiviral therapy interferon alfa treat patient adult T-cell leukemia/lymphoma cause HTLV-1 .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Antiviral Therapy Interferon Alfa Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin ( EPOCH ) follow lamivudine , zidovudine , interferon alfa , term response rate , patient HTLV-1-associated adult T-cell leukemia/lymphoma . - Determine duration response patient treat regimen . - Determine toxicity regimen patient . - Determine effect regimen marker virus replication expression immune function patient . OUTLINE : This multicenter study . Patients receive EPOCH chemotherapy comprise etoposide , vincristine , doxorubicin IV continuously day 1-5 , cyclophosphamide IV 30 minute day 5 , oral prednisone day 1-5 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 7 continue blood count recover . Treatment repeat every 21-28 day least 2 course beyond best response 6 course absence unacceptable toxicity , disease progression , stable disease . Beginning 1 month completion EPOCH , patient receive oral lamivudine zidovudine twice daily interferon alfa SC daily continuously 1 year . Patients follow monthly 1 year , every 2 month 1 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 10-32 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm HTLV1associated adult Tcell leukemia/lymphoma ( ATLL ) Previously treat ATLL allow CD3positive Documented HTLV1 infection serologic assay ( ELISA , Western blot ) Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm^3* Platelet count great 75,000/mm^3* NOTE : *Unless cytopenia secondary ATLL Hepatic : Transaminase le 7 time upper limit normal Bilirubin le 2.0 mg/dL ( unless secondary hepatic infiltration lymphoma isolate indirect hyperbilirubinemia associate indinavir ) Renal : Creatinine le 2.0 mg/dL ( unless due lymphoma ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study completion No active opportunistic infection require acute therapy No untreated thyroid disease No autoimmune disease No uncontrolled significant psychiatric disease No concurrent malignancy except carcinoma situ cervix nonmetastatic nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 24 hour since prior hematologic growth factor Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Concurrent chronic therapy potentially myelosuppressive agent allow Other concurrent antiretroviral therapy HIV , hepatitis B , hepatitis C infection ( indication ) allow investigator 's discretion patient receive therapy prior study initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
</DOC>